“…Despite has been huge described scientific progress in oncology, cancer therapy is still hindered by the absence of reliable early diagnosis methods (Missel et al, 2015;Fitch, 2019;Behrend et al, 2003). Over the last decade, considerable progress has been achieved in cancer screening using different kinds of markers, such as genetic and epigenetic changes in nuclear DNA (Komerik et al, 2017) and quantitative changes in circulating RNAs (Di et al, 2019). However, these screening methods have certain disadvantages, such as invasiveness, high cost, and difficulties in the result interpretation related to the complexity of nuclear genome (Yu, 2011).…”